A 72-year-old woman was found to have massive bilateral adrenal masses on computed tomography and was diagnosed with 21-hydroxylase deficiency (21-OHD) based on endocrinological findings. Physical examination revealed no abnormalities except markedly short stature. She was diagnosed with 21-OHD because she had an elevated serum 17a-hydroxyprogesterone (17-OHP) level which significantly decreased in response to dexamethasone. Percutaneous CT-guided biopsy and later autopsy confirmed that the adrenal masses were due to adrenocortical hyperplasia.
21-HYDROXYLASE deficiency (21-OHD) is among the most common inherited disorders and accounts for 90-95% of congenital adrenal hyperplasia (CAH) cases [1 , 2] . The two major classic disease phenotypes of 21-OHD are the salt wasting (SW) and simple virilizing (SY) forms. Nonclassical 21-OHD (NC), a milder form of the disease, is distinguished from the classical 21-OHD. Most untreated CAH patients including 21-OHD patients have adrenal masses [3, 4] . Recently, several cases of adrenal masses have been discovered incidentally on computed tomography (CT) and further work-up showed they had 21-OHD [5, 6] . The 21-hydroxylase enzyme is encoded by the functional CYP2J gene, which is nearly identical with CYP21 P pseudogene. Recent studies suggest that the various phenotypes of 21-OHD correspond with particular mutations in the CYP21 gene [7] [8] [9] , whereas it has been reported that the genotype does not always predict the phenotype [9, 10] .
Here we report a case of 21-OHD diagnosed when bilateral adrenal masses were discovered on CT at age 72. We also discuss the diagnosis of adrenal mass and the relationship between the 21-OHD phenotype and CYP2J genotype. (Table 2 -a). On ACTH stimulation test, serum cortisol increased within a twofold higher level from the basal level. These findings suggested slight adrenocortical insufficiency and therefore the levels of various adrenocortical steroids were measured (Table 1 -a). The patient had high levels of urinary 17-ketosteroids (17-KS), pregnanetriol, and 1 1-deoxy-ketogenicsteroids/1 1-oxy-ketogenicsteroids ratio (11-deoxy-KGS/ 11-oxy-KGS ratio), and all were significantly suppressed in response to dexamethasone suppression test (Table 2-b) .
Upper abdominal CT and magnetic resonance imaging (MRI) showed a left adrenal gland of 53 x 18 mm in size and a right adrenal gland of 32 x 23 Table 1 . The dehydroepiandrosteronesulphate (DHEA-S), androstendione and testosterone levels in the blood samples obtained from these four points were nearly equal.
After obtaining informed consent from the patient, a genomic DNA sample was extracted from her blood leukocytes and the CYP21 gene was analyzed. Large deletions were not detected in the CYP21 gene by Southern blot analysis method described previously [11] .
To identify point mutations, polymerase chain reaction (PCR)-restriction enzyme analysis was performed, as described previously [11] . Among the known deleterious mutations of the CYP21 gene causing 21-OHD, we analyzed the intron 2 mutation (C or A nucleotide-G nucleotide), exon 4 mutation (Ile-172--Asn, E4IN), exon 7 mutation (Val-281 -~Leu) and exon 8 mutation (Gln-318--~Stop) .
The primer pairs which we used to amplify specific regions of the CYP21 gene are shown in Table 3 . Each of the PCR products was digested with the appropriate restriction enzyme, according to the manufacturer's recommended protocols (Boehringer Mannheim, Mannheim, Germany). After digestion, the reaction mixture was electrophoresed on a 2.5% agarose gel for 45 min at 100 mV. Only the heterozygous E4IN mutation was detected by PCR-restriction enzyme analysis (Fig. 2) .
To further analyze the CYP21 gene of the patient, DNA sequence analysis was performed according to the chain-termination method described previously [11]. For PCR followed by direct sequence analysis, the following primer pairs were used: G-H, I-J (Fig. 3) . To detect which allele carries the E4IN mutation and the E38dl deletion, another PCR-restriction enzyme analysis was performed using primer pair M-J. Primer pair M-J was set up not to amplify the allele which carries the E3gd1 deletion.
The E4IN mutation was detected by this analysis, indicating that the E4IN mutation and the E3gd1 deletion are present on different alleles of the CYP2J gene.
After admission, all inflammatory findings disappeared without any treatment.
Since the patient was diagnosed with 21-OHD, treatment with 0.5 mg/day oral dexamethasone was started, and the ACTH level was suppressed to less than 5.0 pg/ml. Later, the dosage of dexamethasone was decreased to 0.5 mg every two days and she was discharged. In May 1995, a metastatic liver tumor was detected on CT. The histologic diagnosis of the bilateral masses was adrenocortical hyperplasia. Fig. 2 . Electrophoretic analysis of digested PCR products of the CYP21 gene of the patient for detection of the intron 2 mutation (I2 g), the exon 4 mutation (E4IN), the exon 7 mutation (E7VL), and the exon 8 mutation (E8non). Lane M: molecular weight marker (cX174-HaeIIIdigest: Takara Shuzo Co. Ltd., Kyoto, Japan). Lanes 1-3: Sau3AI-digested PCR products of primer pair A-B were separated by electrophoresis for detection of the I2g mutation.
The patient (lane 1) showed only a 154-bp fragment, indicating that she does not have the I2g mutation.
Lanes 4-6: TagI-digested PCR products of primer pair C-D were separated by electrophoresis for detection of the E4IN mutation. The patient (lane 4) showed 420-bp and 397-bp fragments, similar to the heterozygous control (lane 6), indicating that she is a heterozygote for the E4IN mutation.
Lanes 7-8: PmacI-digested (lane 7) and ApaLI-digested (lane 8) PCR products of primer pair E-F were separated by electrophoresis for detection of the E7VL mutation.
Lane 7 showed 310-bp and 471-bp fragments. Lane 8 showed 375-bp, 311-bp and 95-bp fragments.
These results indicate that she does not have the E7VL mutation.
Lane 9: PstI-digested PCR products of primer pair E-F were separated by electrophoresis for detection of the E8non mutation.
The patient showed 299-bp, 204-bp, 158-bp and 120-bp fragments, indicating that she does not have the E8non mutation.
Discussion
Our patient was diagnosed with 21-OHD because she had elevated levels of serum 17-OHP, urinary pregnanetriol, and urinary 11-deoxy-KGS/11-oxy-KGS ratio, all of which decreased in response to dexamethasone.
She denied any history of saltwasting episodes and had few symptoms except for markedly short stature which is considered to be associated with 21-OHD.
The clinical diagnosis is commonly confirmed by analysis of the CYP21 gene [7] [8] [9] . Our patient was a compound heterozygote for the E4IN mutation and the E3gd1 deletion. The E38d1 deletion renders the gene nonfunctional by generating premature termination [8] , and this deletion is often detected in the CYP21 gene of SW patients [13] . The E4IN mutation reduces 21-hydroxylase enzyme activity to less than 10% of normal activity [8] , and this mutation is often found in the CYP21 gene of SV patients [9, 14] . Therefore, a compound heterozygote for these two nucleotide alterations should result in the SV phenotype, considering that 21-OHD is an autosomal recessive disease. Speiser et al. investigated the relationship between 17-OHP level and phenotype of 21-OHD, and reported that the basal level of serum 17-OHP in SV patients is usually > 300 nmol/1(99 ng/ml), while NC patients have a lower basal level of 17-OHP [9] . In our case, the serum 17-OHP level was higher than that of typical NC and near to that of typical SV. As most untreated CAH patients including 21-OHD patients have adrenal masses [3, 4] , our patient was diagnosed as having 21-OHD when bilateral adrenal masses were incidentally discovered on CT. Jaresch et al. examined 22 patients with homozygous CAH (of which 20 patients had 21-OHD) who were under replacement therapy with hydrocortisone, and reported that adrenal tumors were detected in 82% of the patients on CT [4] . Twenty siblings of the 22 homozygous CAH patients were diagnosed with heterozygous CAH (of which 19 siblings had 21-OHD), and adrenal tumors were detected in 45% of the siblings with heterozygous CAH. Therefore, in order to detect NC or heterozygous CAH, patients with adrenal masses should have an ACTH stimulation test unless the cause of the mass is otherwise evident [5] . Small incidentalomas are markedly less likely to be carcinomas than large incidentalomas. Therefore, Ravichandran et al, mentioned that CAH patients with smaller incidentalomas should be followed both clinically and with periodic CT scans, and that biopsy or surgery need not be routine [5] . In our patient, as both adrenal masses exceeded 3 cm in diameter and the inner part of the masses showed heterogeneity, adrenocortical carcinoma could not be completely ruled out. Therefore, percutaneous CTguided biopsy was performed. Efforts should be made to check for 21-OHD in patients with adrenal masses discovered incidentally, to avoid excessive examination and surgery. The PCR product of primer pair I-J was subjected to PCR-direct sequence analysis. In the sequence ladder of the control, only normal sequence was present. In the sequence ladder of the patient, two different sequences were present. The sequence represented on the left in the sequence ladder is normal, while the sequence represented on the right in the sequence ladder lacks the sequence "GAGACTAC" (nucleotide number 707 to 714 [12] ). This finding indicates that the patient is a heterozygote for the 8-nucleotide deletion in exon 3 (E3gd1).
